Analysts Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $37.56

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been given an average rating of "Moderate Buy" by the nineteen research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $37.56.

NTLA has been the topic of a number of analyst reports. The Goldman Sachs Group restated a "sell" rating and issued a $9.00 price target on shares of Intellia Therapeutics in a research note on Friday, February 28th. Barclays reduced their price objective on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. BMO Capital Markets lowered their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating on the stock in a research report on Friday, January 10th. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Finally, Citigroup upped their price target on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a "neutral" rating in a report on Friday, February 28th.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds have recently modified their holdings of NTLA. GF Fund Management CO. LTD. bought a new stake in shares of Intellia Therapeutics during the 4th quarter worth about $25,000. Sterling Capital Management LLC grew its stake in Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock valued at $37,000 after buying an additional 2,867 shares during the last quarter. Whipplewood Advisors LLC acquired a new position in Intellia Therapeutics during the 4th quarter worth $40,000. Resona Asset Management Co. Ltd. acquired a new stake in shares of Intellia Therapeutics in the fourth quarter valued at about $43,000. Finally, Jones Financial Companies Lllp increased its stake in shares of Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock worth $45,000 after purchasing an additional 2,280 shares during the period. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Stock Up 5.4 %

NTLA traded up $0.37 on Tuesday, hitting $7.23. 2,864,822 shares of the company traded hands, compared to its average volume of 2,345,128. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.18. The company has a 50 day moving average of $8.89 and a 200-day moving average of $12.19. The stock has a market capitalization of $748.43 million, a PE ratio of -1.33 and a beta of 2.23.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.